|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Centre Hospitalier Universitaire de Saint Etienne |
|---|---|
| Information provided by: | Centre Hospitalier Universitaire de Saint Etienne |
| ClinicalTrials.gov Identifier: | NCT00521508 |
Purpose
Along structural IgA abnormalities, hyperproduction of IgA is thought to play a role in the pathogenesis of primary IgA nephropathy. CD4+CD25+Fox3P regulatory T cells are instrumental in suppressing adaptative immune responses, including B cells production of immunoglobulins. We, the researchers at Centre Hospitalier Universitaire de Saine Etienne, will test the hypothesis that IgA production in patients with IgA nephropathy is dysregulated because of a quantitative and/or qualitative defect of CD4+CD25+FoxP3+ regulatory T cells.
| Condition | Intervention |
|---|---|
|
Glomerulonephritis, IGA |
Procedure: gene transcription and cytometry |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Diagnostic |
| Official Title: | Role of CD4+CD25+FoxP3+ Regulatory T Cells in Pathogenesis of Primary IgA Nephropathy |
| Estimated Enrollment: | 45 |
| Study Start Date: | April 2008 |
| Study Completion Date: | September 2010 |
| Primary Completion Date: | April 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
1
Patient affected by Berger's disease confirmed by renal biopsy with increased rate of Ig A
|
Procedure: gene transcription and cytometry
samply of 30 ml of blood
|
|
2
Patient affected by Berger's disease with normal rate of Ig A
|
Procedure: gene transcription and cytometry
samply of 30 ml of blood
|
|
3
Healthy volunteers
|
Procedure: gene transcription and cytometry
samply of 30 ml of blood
|
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| France | |
| Nephrology Unit Hôpital Nord CHU de Saint-Etienne | |
| Saint-Etienne, France, 42055 | |
| Principal Investigator: | Christophe MARIAT, MD PhD | CHU Saint-Etienne |
More Information
| Responsible Party: | Clément CAILLAUX, CHU Saint-Etienne |
| ClinicalTrials.gov Identifier: | NCT00521508 History of Changes |
| Other Study ID Numbers: | 0608118, 2007-A00129-44, DGS 2007-0184 |
| Study First Received: | August 27, 2007 |
| Last Updated: | September 28, 2010 |
| Health Authority: | France: Afssaps - French Health Products Safety Agency; France: French Data Protection Authority |
|
IgA kidney Berger'disease regulatory T cells pathogenesis of Berger's disease |
|
Glomerulonephritis Glomerulonephritis, IGA Kidney Diseases Nephritis |
Urologic Diseases Autoimmune Diseases Immune System Diseases |